Home > Newsletters > Drug Industry Daily > Forest Gets Untitled Letter After Reps Tout Weight Loss Adverse Event as Potentially Beneficial
Drug Industry Daily
Aug. 8, 2012 | Vol. 11 No. 155
Forest Gets Untitled Letter After Reps Tout Weight Loss Adverse Event as Potentially Beneficial
Forest Laboratories has been hit with an untitled letter after two of its sales reps implied that weight loss while using Daliresp tablets — listed as an adverse reaction — could be beneficial for overweight chronic obstructive pulmonary disease (COPD) patients.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.